A 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess longterm safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis (CLARITY)
Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.
Key Inclusion Criteria:
Chronic plaque-type psoriasis present for at least 6 months and diagnosed before randomization
Moderate to severe plaque psoriasis
Candidate for systemic therapy, defined as having psoriasis inadequately controlled by:
Topical treatment (including topical corticosteroids) and/or
Previous systemic therapy
David Smith, M.D.